List of works - Athina Giannoudis

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

scientific article published on 11 January 2010

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

scientific article published on 13 April 2011

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

scientific article published on 27 August 2009

Detection of Epstein-Barr virus and human papillomavirus in nasopharyngeal carcinoma by the polymerase chain reaction technique

scientific article

Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia ⬇️

scientific article published on July 1, 1994

Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia

scientific article published on 4 September 2014

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

scientific article

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

scientific article

Human papillomavirus in pterygium.

scientific article

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

scientific article published on 7 July 2015

Lamotrigine is a substrate for OCT1 in brain endothelial cells

scientific article published on 29 December 2011

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia

scientific article

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.

scientific article published in July 2004

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

scientific article

Peroxisome proliferator–activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells

scientific article published on 05 June 2012

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia

scientific article published on April 2008

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

scientific article published on 22 August 2014

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia

scientific article published on 20 January 2014

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

scientific article published on 5 December 2012

Transport of gabapentin by LAT1 (SLC7A5).

scientific article published on 6 April 2013

Use of macrophages to target therapeutic adenovirus to human prostate tumors

scientific article published on 13 January 2011

c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

scientific article published on 6 February 2015

List of works by Athina Giannoudis

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Detection of Epstein-Barr virus and human papillomavirus in nasopharyngeal carcinoma by the polymerase chain reaction technique

Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia ⬇️

Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

Human papillomavirus in pterygium.

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

Lamotrigine is a substrate for OCT1 in brain endothelial cells

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

Peroxisome proliferator–activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Transport of gabapentin by LAT1 (SLC7A5).

Use of macrophages to target therapeutic adenovirus to human prostate tumors

c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia